---
reference_id: "PMID:34726479"
title: An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19.
authors:
- Owen DR
- Allerton CMN
- Anderson AS
- Aschenbrenner L
- Avery M
- Berritt S
- Boras B
- Cardin RD
- Carlo A
- Coffman KJ
- Dantonio A
- Di L
- Eng H
- Ferre R
- Gajiwala KS
- Gibson SA
- Greasley SE
- Hurst BL
- Kadar EP
- Kalgutkar AS
- Lee JC
- Lee J
- Liu W
- Mason SW
- Noell S
- Novak JJ
- Obach RS
- Ogilvie K
- Patel NC
- Pettersson M
- Rai DK
- Reese MR
- Sammons MF
- Sathish JG
- Singh RSP
- Steppan CM
- Stewart AE
- Tuttle JB
- Updyke L
- Verhoest PR
- Wei L
- Yang Q
- Zhu Y
journal: Science
year: '2021'
doi: 10.1126/science.abl4784
content_type: abstract_only
---

# An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19.
**Authors:** Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, Boras B, Cardin RD, Carlo A, Coffman KJ, Dantonio A, Di L, Eng H, Ferre R, Gajiwala KS, Gibson SA, Greasley SE, Hurst BL, Kadar EP, Kalgutkar AS, Lee JC, Lee J, Liu W, Mason SW, Noell S, Novak JJ, Obach RS, Ogilvie K, Patel NC, Pettersson M, Rai DK, Reese MR, Sammons MF, Sathish JG, Singh RSP, Steppan CM, Stewart AE, Tuttle JB, Updyke L, Verhoest PR, Wei L, Yang Q, Zhu Y
**Journal:** Science (2021)
**DOI:** [10.1126/science.abl4784](https://doi.org/10.1126/science.abl4784)

## Content

1. Science. 2021 Dec 24;374(6575):1586-1593. doi: 10.1126/science.abl4784. Epub 
2021 Nov 2.

An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of 
COVID-19.

Owen DR(1), Allerton CMN(1), Anderson AS(2), Aschenbrenner L(3), Avery M(3), 
Berritt S(3), Boras B(4), Cardin RD(2), Carlo A(3), Coffman KJ(3), Dantonio 
A(3), Di L(3), Eng H(3), Ferre R(4), Gajiwala KS(4), Gibson SA(5), Greasley 
SE(4), Hurst BL(5), Kadar EP(3), Kalgutkar AS(1), Lee JC(3), Lee J(3), Liu W(4), 
Mason SW(2), Noell S(3), Novak JJ(3), Obach RS(3), Ogilvie K(3), Patel NC(1), 
Pettersson M(1), Rai DK(2), Reese MR(3), Sammons MF(1), Sathish JG(2), Singh 
RSP(1), Steppan CM(3), Stewart AE(4), Tuttle JB(1), Updyke L(1), Verhoest PR(1), 
Wei L(3), Yang Q(1), Zhu Y(2).

Author information:
(1)Pfizer Worldwide Research, Development & Medical, Cambridge, MA 02139, USA.
(2)Pfizer Worldwide Research, Development & Medical, Pearl River, NY 10965, USA.
(3)Pfizer Worldwide Research, Development & Medical; Groton, CT 06340, USA.
(4)Pfizer Worldwide Research, Development & Medical, La Jolla, CA 92121, USA.
(5)Institute for Antiviral Research, Department of Animal, Dairy, and Veterinary 
Sciences, Utah State University; Logan, UT 84322, USA.

The worldwide outbreak of COVID-19 caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, 
antiviral therapeutics are an important part of the healthcare response to 
countering the ongoing threat presented by COVID-19. Here, we report the 
discovery and characterization of PF-07321332, an orally bioavailable SARS-CoV-2 
main protease inhibitor with in vitro pan-human coronavirus antiviral activity 
and excellent off-target selectivity and in vivo safety profiles. PF-07321332 
has demonstrated oral activity in a mouse-adapted SARS-CoV-2 model and has 
achieved oral plasma concentrations exceeding the in vitro antiviral cell 
potency in a phase 1 clinical trial in healthy human participants.

DOI: 10.1126/science.abl4784
PMID: 34726479 [Indexed for MEDLINE]